Acceleron Pharma (Acceleron Pharma) Revenue per Share : $1.86 (TTM As of Sep. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma Revenue per Share?

Acceleron Pharma's revenue per share for the three months ended in Sep. 2021 was $0.56. Acceleron Pharma's revenue per share for the trailing twelve months (TTM) ended in Sep. 2021 was $1.86.

Warning Sign:

Acceleron Pharma Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue Per Share Growth Rate of Acceleron Pharma was -4.10% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 69.60% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 23.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Acceleron Pharma's Revenue per Share or its related term are showing as below:

XLRN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -50.4 Med: -10.4 Max: 69.6
Current: 69.6

During the past 10 years, Acceleron Pharma's highest 3-Year average Revenue Per Share Growth Rate was 69.60% per year. The lowest was -50.40% per year. And the median was -10.40% per year.

XLRN's 3-Year Revenue Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.4 vs XLRN: 69.60

Acceleron Pharma Revenue per Share Historical Data

The historical data trend for Acceleron Pharma's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acceleron Pharma Revenue per Share Chart

Acceleron Pharma Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Revenue per Share

Get a 7-Day Free Trial

0.74

0.33

0.31

1.41

1.63

Acceleron Pharma Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Revenue per Share	Get a 7-Day Free Trial															0.38	0.43	0.41	0.46	0.56

Competitive Comparison of Acceleron Pharma's Revenue per Share

For the Biotechnology subindustry, Acceleron Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acceleron Pharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acceleron Pharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Acceleron Pharma's PS Ratio falls into.

Acceleron Pharma Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Acceleron Pharma's Revenue Per Share for the fiscal year that ended in Dec. 2020 is calculated as

Revenue Per Share (A: Dec. 2020 )	=	Revenue (A: Dec. 2020 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2020 )
	=	92.523	/	56.800
	=	1.63

Acceleron Pharma's Revenue Per Share for the quarter that ended in Sep. 2021 is calculated as

Revenue Per Share (Q: Sep. 2021 )	=	Revenue (Q: Sep. 2021 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2021 )
	=	34.199	/	60.937
	=	0.56

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.86

Acceleron Pharma (NAS:XLRN) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Acceleron Pharma Revenue per Share Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Acceleron Pharma (Acceleron Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Sidney Street, Cambridge, MA, USA, 02139

Website

http://www.acceleronpharma.com

Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.

Executives

Sujay Kango	officer: EVP, Chief Commercial Officer	1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin	officer: SVP, CFO and Treasurer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness	officer: SVP, General Counsel and Sec.	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable	director, officer: CEO and President	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co	10 percent owner	430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/	10 percent owner	86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George	director	CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik	director	C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139